The genetic status of IDH1/2 and EGFR dictates the vascular landscape and the progression of gliomas
preprint
OA: closed
Abstract
Rationale Glioma progression is driven by the induction of vascular alterations but how the tumor genotype influence these changes is still a pending issue. We propose to study the underlying mechanisms by which the genetic changes in isocitrate dehydrogenase 1/2 ( IDH1/2 ) and epidermal growth factor receptor ( EGFR ) genes establish the different vascular profiles of gliomas. Methods We stratified gliomas based on the genetic status of IDH1/2 and EGFR genes. For that we used in silico data and a cohort of 93 glioma patients, where we analyzed the expression of several transcripts and proteins. For the in vitro and in vivo studies, we used a battery of primary glioblastoma cells derived from patients, as well as novel murine glioma cell lines expressing wild-type or mutant EGFR. In these models, the effect of the small molecule ibrutinib or the downregulation of CD248 and SOX9 was evaluated to establish a molecular mechanism. Results We show that IDH1/2 mutations associate with a normalized vasculature. By contrast, EGFR mutations stimulate the plasticity of glioma cells and their capacity to function as pericytes in a bone-marrow and X-linked (BMX)/SOX9 dependent manner. The presence of tumor-derived pericytes stabilize the profuse vasculature and confers a growth advantage to these tumors, although they render them sensitive to pericyte-targeted molecules. Wild-type/amplified EGFR gliomas are enriched in blood vessels too, but they show a highly disrupted blood-brain-barrier due to a decreased BMX/SOX9 activation and pericyte coverage. This leads to poor nutrient supply, necrosis and hypoxia. Conclusions The function of tumor-derived pericytes delimitates two distinct and aggressive vascular phenotypes in IDH1/2 wild-type gliomas. Our results lay the foundations for a vascular dependent stratification of gliomas and suggest different therapeutic vulnerabilities depending on the genetic status of EGFR . Graphical Abstract. Schematic view of IDH and EGFR function in the regulation of glioma microenvironment. Mutant IDH gliomas express low levels of angiogenic molecules and have a vasculature reminiscent of normal tissue. EGFR mutations drive glioma growth by promoting tumor-to-pericyte transdifferentiation and vascular stabilization in a BMX-SOX9 dependent way. Leaky vessels with hypoxia and necrosis characterize tumors overexpressing the wild-type isoform of the receptor. These phenotypes determine the response to therapy of the different IDH wild-type gliomas.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (45)
- doi:10.1007/s00401-016-1545-1 via crossref
- doi:10.1016/j.ajpath.2012.06.030 via crossref
- doi:10.1016/j.cell.2013.02.021 via crossref
- doi:10.1016/j.ccell.2016.10.018 via crossref
- doi:10.1007/s11060-016-2269-8 via crossref
- doi:10.1126/scitranslmed.aax1501 via crossref
- doi:10.1007/s00018-014-1608-1 via crossref
- doi:10.3390/ijms18061295 via crossref
- doi:10.1158/1535-7163.mct-14-0736 via crossref
- doi:10.1038/s41398-018-0095-9 via crossref
- doi:10.1093/neuonc/noy088 via crossref
- doi:10.1038/nrclinonc.2014.126 via crossref
- doi:10.1007/s10456-014-9432-7 via crossref
- doi:10.1016/j.ccell.2014.10.006 via crossref
- doi:10.1016/j.ccr.2009.12.020 via crossref
- doi:10.1073/pnas.1314341111 via crossref
- doi:10.1016/j.ccr.2006.02.019 via crossref
- doi:10.1200/jco.2010.33.8715 via crossref
- doi:10.1038/modpathol.3801006 via crossref
- doi:10.3389/fnagi.2019.00231 via crossref
- doi:10.1016/j.molcel.2015.09.002 via crossref
- doi:10.1016/j.ccell.2020.06.003 via crossref
- doi:10.1155/2019/6754040 via crossref
- doi:10.1016/j.stem.2017.10.002 via crossref
- doi:10.1093/neuonc/now113 via crossref
- doi:10.1186/1476-4598-12-31 via crossref
- doi:10.3174/ajnr.a4484 via crossref
- doi:10.3174/ajnr.a4774 via crossref
- doi:10.1038/nrclinonc.2012.2 via crossref
- doi:10.1093/neuonc/noy033 via crossref
- doi:10.1093/neuonc/noy066 via crossref
- doi:10.3816/clc.2006.n.002 via crossref
- doi:10.1073/pnas.0702387104 via crossref
- doi:10.2174/138161213804547259 via crossref
- doi:10.1016/j.ccr.2005.08.002 via crossref
- doi:10.1016/j.ccr.2008.01.034 via crossref
- doi:10.1126/scitranslmed.aah6816 via crossref
- doi:10.1038/s41588-018-0209-6 via crossref
- doi:10.1093/jnci/dju204 via crossref
- doi:10.1007/s12032-012-0267-z via crossref
- doi:10.1517/14728222.2016.1151002 via crossref
- doi:10.1038/s41598-019-57047-w via crossref
- doi:10.1242/dev.010454 via crossref
- doi:10.1074/jbc.m707729200 via crossref
- doi:10.1038/nm.4415 via crossref
Source provenance
- crossref
- last seen: 2026-07-13T06:45:25.004778+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-07-13T06:45:44.122212+00:00